Cwm LLC Has $44.35 Million Stake in Amgen Inc. $AMGN

Cwm LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 1.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 157,141 shares of the medical research company’s stock after purchasing an additional 2,723 shares during the quarter. Cwm LLC’s holdings in Amgen were worth $44,345,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Wealth Preservation Advisors LLC bought a new position in Amgen in the first quarter valued at approximately $25,000. Legacy Investment Solutions LLC bought a new stake in Amgen in the 2nd quarter valued at $27,000. CBIZ Investment Advisory Services LLC lifted its position in Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP acquired a new position in Amgen in the 2nd quarter worth $32,000. Finally, Howard Hughes Medical Institute bought a new position in Amgen during the 2nd quarter worth about $32,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AMGN. Daiwa Capital Markets boosted their price target on Amgen from $310.00 to $370.00 and gave the company an “outperform” rating in a report on Tuesday, November 18th. Erste Group Bank upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Friday, December 5th. Bank of America raised their price target on shares of Amgen from $261.00 to $272.00 and gave the stock an “underperform” rating in a research note on Friday, September 26th. Morgan Stanley lowered their price objective on shares of Amgen from $329.00 to $304.00 and set an “equal weight” rating on the stock in a report on Friday, December 12th. Finally, Piper Sandler raised their target price on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $332.85.

Amgen Price Performance

Shares of AMGN opened at $332.50 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The company’s fifty day simple moving average is $322.29 and its 200 day simple moving average is $301.33. Amgen Inc. has a 1-year low of $257.05 and a 1-year high of $346.38. The company has a market cap of $179.04 billion, a price-to-earnings ratio of 25.70, a PEG ratio of 3.10 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 EPS for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion during the quarter, compared to analysts’ expectations of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same quarter last year, the company posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a $2.52 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 3.0%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is currently 73.57%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction that occurred on Thursday, November 20th. The stock was sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the transaction, the senior vice president directly owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 10,908 shares of company stock valued at $3,674,966 over the last three months. Insiders own 0.76% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.